Parametric images via dynamic 18F-fluorodeoxyglucose positron emission tomographic data acquisition in predicting midterm outcome of liver metastases secondary to gastrointestinal stromal tumours

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 7, 2011, Pages 1212-1223

  Apostolopoulos, Dimitris J ^a,b   Dimitrakopoulou Strauss, Antonia ^a   Hohenberger, Peter ^c   Roumia, Safwan ^a   Strauss, Ludwig G ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Dynamic 18F FDG PET; Gastrointestinal stromal tumours; Liver metastases; Molecular targeted therapy; Parametric images

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; SUNITINIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; DISCRIMINANT ANALYSIS; DISEASE ACTIVITY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMAGE ANALYSIS; INFORMATION PROCESSING; LIVER METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; VOXEL BASED MORPHOMETRY;

ADULT; AGED; COHORT STUDIES; DISCRIMINANT ANALYSIS; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LINEAR MODELS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 79958038176     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1776-2     Document Type: Article

References (37)

1. RS Benjamin M Debiec-Rychter A Le Cesne S Sleijfer GD Demetri H Joensuu, et al. 2009 Gastrointestinal stromal tumours II: medical oncology and tumour response assessment Semin Oncol 36 302 311 19664491 10.1053/j.seminoncol.2009. 06.003 1:CAS:528:DC%2BD1MXhtFWjt7fF
2. CD Blanke GD Demetri M von Mehren MC Heinrich B Eisenberg JA Fletcher, et al. 2008 Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 620 625 18235121 10.1200/JCO.2007.13.4403 1:CAS:528:DC%2BD1cXis1alsL0%3D (Pubitemid 351264357)
3. JS Gold SM van der Zwan M Gönen RG Maki S Singer MF Brennan, et al. 2007 Outcome of metastatic GIST in the era before tyrosine kinase inhibitors Ann Surg Oncol 14 134 142 17080234 10.1245/s10434-006-9177-7 (Pubitemid 44954280)
4. S Duensing A Duensing 2010 Targeted therapies of gastrointestinal stromal tumors (GIST)-the next frontiers Biochem Pharmacol 80 575 583 20385106 10.1016/j.bcp.2010.04.006 1:CAS:528:DC%2BC3cXosV2is74%3D
5. AD Van den Abbeele 2008 The lessons of GIST-PET and PET/CT: a new paradigm for imaging Oncologist 13 Suppl 2 8 13 18434632 10.1634/theoncologist. 13-S2-8
6. JO Prior M Montemurro MV Orcurto O Michielin F Luthi J Benhattar, et al. 2009 Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor J Clin Oncol 27 439 445 19064982 10.1200/JCO.2008.17.2742 1:CAS:528:DC%2BD1MXitF2gtr8%3D
7. M Mabille D Vanel M Albiter A Le Cesne S Bonvalot C Le Péchoux, et al. 2009 Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!) Eur J Radiol 69 204 208 19046841 10.1016/j.ejrad.2008.10.009
8. GW Goerres R Stupp G Barghouth TF Hany B Pestalozzi E Dizendorf, et al. 2005 The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate Eur J Nucl Med Mol Imaging 32 153 162 15690223 10.1007/s00259-004-1633-7 1:CAS:528:DC%2BD2MXpsFyktQ%3D%3D (Pubitemid 40248485)
9. S Stroobants J Goeminne M Seegers S Dimitrijevic P Dupont J Nuyts, et al. 2003 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec) Eur J Cancer 39 2012 2020 12957455 10.1016/S0959-8049(03)00073-X 1:CAS:528: DC%2BD3sXmvVKgt74%3D (Pubitemid 37297757)
10. H Choi C Charnsangavej S de Castro Faria EP Tamm RS Benjamin MM Johnson, et al. 2004 CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings AJR Am J Roentgenol 183 1619 1628 15547201 (Pubitemid 44210530)
11. CL Scaife KK Hunt SR Patel RS Benjamin MA Burgess LL Chen, et al. 2003 Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 186 665 669 14672776 10.1016/j.amjsurg.2003.08.023 (Pubitemid 37522103)
12. L Sokoloff 1983-1984 Mapping local functional activity by measurement of local cerebral glucose utilization in the central nervous system of animals and man Harvey Lect 79 77 143 1:CAS:528:DyaL28XosFOluw%3D%3D
13. CS Patlak RG Blasberg 1985 Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations J Cereb Blood Flow Metab 5 584 590 4055928 10.1038/jcbfm.1985.87 1:STN:280: DyaL28%2FjsVahuw%3D%3D (Pubitemid 16218234)
14. C Burger A Buck 1997 Requirements and implementation of a flexible kinetic modeling tool J Nucl Med 38 1818 1823 9374364 1:STN:280: DyaK1c%2FktVGhsg%3D%3D (Pubitemid 27495539)
15. KC Schmidt FE Turkheimer 2002 Kinetic modeling in positron emission tomography Q J Nucl Med 46 70 85 12072847 1:STN:280:DC%2BD38zjtVSitQ%3D%3D (Pubitemid 34808740)
16. A Dimitrakopoulou-Strauss M Hoffmann R Bergner M Uppenkamp M Eisenhut L Pan, et al. 2007 Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18] fluoro-D-glucose-positron emission tomography: a feasibility study Mol Imaging Biol 9 308 317 17623254 10.1007/s11307-007-0103-6 (Pubitemid 47304781)
17. A Dimitrakopoulou-Strauss L Pan LG Strauss 2010 Parametric imaging: a promising approach for the evaluation of dynamic PET-18F-FDG studies-the DKFZ experience Hell J Nucl Med 13 18 22 20411165
18. C Messa Y Choi CK Hoh EL Jacobs JA Glaspy S Rege, et al. 1992 Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET J Comput Assist Tomogr 16 684 689 1522257 10.1097/00004728-199209000-00003 1:STN:280:DyaK38zpsFajtg%3D%3D
19. Afifi A, Clark VA, May S. Computer-aided multivariate analysis. 4th ed. Boca Raton: Chapman & Hall/CRC; 2004.
20. MC Tan DC Linehan WG Hawkins BA Siegel SM Strasberg 2007 Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response J Gastrointest Surg 11 1112 1119 17623263 10.1007/s11605-007-0218-8
21. N Lubezky U Metser R Geva R Nakache E Shmueli JM Klausner, et al. 2007 The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings J Gastrointest Surg 11 472 478 17436132 10.1007/s11605-006-0032-8
22. LG Strauss A Dimitrakopoulou-Strauss 2007 Can PET-CT with FDG replace contrast enhanced CT for imaging of liver metastases? Eur J Nucl Med Mol Imaging 34 1902 1905 17938920 10.1007/s00259-007-0619-7 (Pubitemid 350212150)
23. S Bipat MS van Leeuwen EF Comans ME Pijl PM Bossuyt AH Zwinderman, et al. 2005 Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis Radiology 237 123 131 16100087 10.1148/radiol.2371042060 (Pubitemid 41346155)
24. A Gronchi M Fiore F Miselli MS Lagonigro P Coco A Messina, et al. 2007 Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST Ann Surg 245 341 346 17435538 10.1097/01.sla.0000242710.36384.1b (Pubitemid 46673127)
25. E Wardelmann N Thomas S Merkelbach-Bruse K Pauls N Speidel R Büttner, et al. 2005 Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations Lancet Oncol 6 249 251 15811621 10.1016/S1470-2045(05)70097-8 1:CAS:528:DC%2BD2MXjtlWjtLY%3D (Pubitemid 40450717)
26. YJ Ye ZD Gao GJ Poston S Wang 2009 Diagnosis and multi-disciplinary management of hepatic metastases from gastrointestinal stromal tumour (GIST) Eur J Surg Oncol 35 787 792 19185444
27. H Prenen C Stefan B Landuyt P Vermaelen M Debiec-Rychter M Bollen, et al. 2005 Imatinib mesylate inhibits glucose uptake in gastrointestinal stromal tumor cells by downregulation of the glucose transporters recruitment to the plasma membrane Am J Biochem Biotechnol 1 95 102 10.3844/ajbbsp.2005.95.102 1:CAS:528:DC%2BD2MXht1Cgu77J
28. J Klawitter N Anderson J Klawitter U Christians D Leibfritz SG Eckhardt, et al. 2009 Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study Br J Cancer 100 923 931 19259085 10.1038/sj.bjc.6604946 1:CAS:528:DC%2BD1MXjt1GjsLc%3D
29. S Shankar E vanSonnenberg J Desai PJ DiPiro A Van Den Abbeele GD Demetri 2005 Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate Radiology 235 892 898 15833985 10.1148/radiol.2353040332 (Pubitemid 40695886)
30. AA Lammertsma CJ Hoekstra G Giaccone OS Hoekstra 2006 How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging 33 Suppl 1 16 21 16763817 10.1007/s00259-006-0131-5
31. T Torizuka S Nobezawa S Momiki N Kasamatsu T Kanno E Yoshikawa, et al. 2000 Short dynamic FDG-PET imaging protocol for patients with lung cancer Eur J Nucl Med 27 1538 1542 11083544 10.1007/s002590000312 1:STN:280: DC%2BD3M7jsFaqtA%3D%3D
32. LG Strauss A Dimitrakopoulou-Strauss U Haberkorn 2003 Shortened PET data acquisition protocol for the quantification of 18F-FDG kinetics J Nucl Med 44 1933 1939 14660719 1:CAS:528:DC%2BD2cXjt1Sgtw%3D%3D (Pubitemid 40022139)
33. EU Nitzsche S Hoegerle M Mix I Brink A Otte E Moser, et al. 2002 Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis? Eur J Nucl Med Mol Imaging 29 237 242 11926386 10.1007/s00259-001-0697-x
34. A Dimitrakopoulou-Strauss LG Strauss T Heichel H Wu C Burger L Bernd, et al. 2002 The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions J Nucl Med 43 510 518 11937595 (Pubitemid 34286347)
35. RK Doot LK Dunnwald EK Schubert M Muzi LM Peterson PE Kinahan, et al. 2007 Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF J Nucl Med 48 920 925 17504870 10.2967/jnumed.106.037382 1:CAS:528:DC%2BD2sXhtVert7fM (Pubitemid 46909920)
36. LG Strauss D Koczan S Klippel L Pan C Cheng S Willis, et al. 2008 Impact of angiogenesis-related gene expression on the tracer kinetics of 18F-FDG in colorectal tumors J Nucl Med 49 1238 1244 18632818 10.2967/jnumed.108.051599 1:CAS:528:DC%2BD1cXhtVCqs73P
37. RL Wahl H Jacene Y Kasamon MA Lodge 2009 From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 Suppl 1 122S 150S 19403881 10.2967/jnumed.108.057307 1:CAS:528:DC%2BD1MXmtFahtr8%3D